CSNK1A1 and myelodysplastic syndrome: Recently, CK1α was suggested as therapeutic target for innovative strategies to treat malignancies arising from the hematopoietic system like multiple myeloma (Hu et al., 2014), acute myeloid leukemia (Jaras et al., 2014), or del(5q) myelodysplastic syndrome (Schneider et al., 2014).